Caldera Therapeutics is a clinical stage company developing CLD-423, a first-in-class bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. Supported by leading biotech investors Atlas Venture, LAV, venBio, Omega Funds, Wellington Management and Janus Henderson Investors, Caldera has assembled a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/16/26 | $112,500,000 | Series A |
Atlas Venture Janus Henderson Investors LAV Fund Omega Funds VenBio Wellington Management | undisclosed |
